These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 9437289)

  • 1. Use of statins. Guidelines need to concentrate on reducing overall cardiovascular risk.
    Wierzbicki AS; Reynolds TM
    BMJ; 1997 Dec; 315(7122):1616-7. PubMed ID: 9437289
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of statins. Glasgow has already produced strategy for treatment.
    McMurray J; McGuire A; Raikou M; Morrison C
    BMJ; 1997 Dec; 315(7122):1617-8. PubMed ID: 9437292
    [No Abstract]   [Full Text] [Related]  

  • 3. RE: M Thomas. The change of cost: reference-based pricing and the statins. 1999;15:535-8.
    McNee W
    Can J Cardiol; 1999 Nov; 15(11):1287. PubMed ID: 10841625
    [No Abstract]   [Full Text] [Related]  

  • 4. [2008 National Cardiology Guidelines: Prioritization requires consideration to other factors than scientific studies alone].
    Eklund K; Grip L; Israelsson B; Levin LA; Lindahl B; Wallentin L
    Lakartidningen; 2008 May 7-13; 105(19):1408-9; discussion 1409. PubMed ID: 18574983
    [No Abstract]   [Full Text] [Related]  

  • 5. [Great discrepancies between European, Dutch and Belgian criteria for the use of statins in the prevention of primary cardiovascular disease in family practice].
    Van Diest E; Stoffelen E; Wydooghe L; Van Duppen D; Seuntjens L; Van der Stuyft P
    Ned Tijdschr Geneeskd; 2001 Feb; 145(8):361-6. PubMed ID: 11257816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The change of cost: reference-based pricing and the statins.
    Thomas M
    Can J Cardiol; 1999 May; 15(5):535-8. PubMed ID: 10350662
    [No Abstract]   [Full Text] [Related]  

  • 7. Cholesterol reduction: what can we afford?
    Luepker RV
    Eur Heart J; 2001 May; 22(9):720-1. PubMed ID: 11350101
    [No Abstract]   [Full Text] [Related]  

  • 8. [Ezetimib and simvastatin. Cooperation at receptors of cholesterol metabolism].
    MMW Fortschr Med; 2005 Jul; 147(27-28):50. PubMed ID: 16041947
    [No Abstract]   [Full Text] [Related]  

  • 9. NHF guidelines on the management of dyslipidaemia.
    Mann J; Agnew T
    N Z Med J; 1996 Sep; 109(1029):345. PubMed ID: 8862356
    [No Abstract]   [Full Text] [Related]  

  • 10. Combination statin-fibrate therapy: safety aspects.
    Franssen R; Vergeer M; Stroes ES; Kastelein JJ
    Diabetes Obes Metab; 2009 Feb; 11(2):89-94. PubMed ID: 18518891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Statins in practice of the vascular surgeon and cardiologist].
    Pokrovskiĭ AV; Suntsov DS
    Angiol Sosud Khir; 2009; 15(2):123-7. PubMed ID: 19806952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The human and economic costs of undertreatment with statins.
    Durrington P
    Int J Clin Pract; 2002 Jun; 56(5):357-68. PubMed ID: 12137445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of lipid-lowering treatment according to lipid level.
    Pilote L; Ho V; Lavoie F; Coupal L; Zowall H; Grover SA
    Can J Cardiol; 2005 Jun; 21(8):681-7. PubMed ID: 16003451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Economic feasibility study and reimbursement rules--illustrated by a concrete example].
    Kolenda K; Friis ML
    Ugeskr Laeger; 2008 Apr; 170(15):1257; author reply 1257. PubMed ID: 18472461
    [No Abstract]   [Full Text] [Related]  

  • 15. [Statins and costs of prevented death cases].
    Robberstad T
    Tidsskr Nor Laegeforen; 1997 Nov; 117(28):4131. PubMed ID: 9441454
    [No Abstract]   [Full Text] [Related]  

  • 16. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease.
    Robson J
    Heart; 2008 Oct; 94(10):1331-2. PubMed ID: 18701534
    [No Abstract]   [Full Text] [Related]  

  • 17. Systematic risk assessment key to CVD prevention.
    Savill P
    Practitioner; 2008 Jun; 252(1707):19, 21-2, 25-6. PubMed ID: 18669367
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.
    Jones PH
    Am J Cardiol; 2007 Feb; 99(4A):133B-140B. PubMed ID: 17307065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of statins. Health authorities must work with clinicians to target statins.
    Wakeman AP; Leach RH
    BMJ; 1997 Dec; 315(7122):1618. PubMed ID: 9437293
    [No Abstract]   [Full Text] [Related]  

  • 20. Management of dyslipidaemia - evidence and practical recommendations.
    Nestel PJ; O'Brien R; Nelson M
    Aust Fam Physician; 2008 Jul; 37(7):521-7. PubMed ID: 18592069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.